# Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness

> **NCT00088023** · PHASE1 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 40 (—)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** PT-523 for Injection

## Key facts

- **NCT ID:** NCT00088023
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 40 (—)
- **Last updated:** 2014-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088023, "Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00088023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*